Potent next-gen ISAC targeting Claudin 18.2
Time: 12:30 pm
day: Conference Day 2
Details:
Efficacy in low-antigen-density tumors
Demonstrated superiority to ADCs in preclinical studies
Immunologic memory with epitope spreading provides promise of durable responses and prevents recurrence MTD ≥ 12 mg/kg in NHPs with differentiated toxicology profile from cytotoxic ADCs
Preparing for first-in-human clinical trial
